論文・技術情報追加のお知らせ

1. Drug-induced risk of depression: A 20-year real-world pharmacovigilance analysis based on the FAERS database.

多くの薬剤で抑うつ副作用が報告され、早期発症例が多い

対象DB：FAERS

2. Comparative safety profiling of sodium zirconate cyclosilicate and patiromer using real-world FAERS data: A pharmacovigilance analysis.

高カリウム血症治療薬で副作用差があり注意が必要

対象DB：FAERS

3. A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing Bias.

PPIとCDI関連は抗菌薬併用の影響が大きく直接因果は弱い

対象DB：FAERS

4. Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology.

リフィテグラスト副作用をAIで高精度予測し安全性評価

対象DB：FAERS

5. Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER.

PD-1/PD-L1阻害薬で内分泌系irAEが多く不可逆例も示唆

対象DB：FAERS,JADER

6. Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database.

ソタテルセプトで出血・血液異常や新規心肺系副作用示唆

対象DB：FAERS

7. An Updated Comprehensive Pharmacovigilance Study of Drug- Induced Breast Cancer Based on FDA Adverse Event Reporting System Data.

乳癌治療薬で副作用プロファイルに差があり心毒性など注意

対象DB：FAERS

8. Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.

チルゼパチドで虚血性視神経症の稀だが重篤なリスク示唆

対象DB：FAERS

9. Cutaneous Lymphoma Associated with JAK Inhibitors: A Pharmacovigilance Analysis of the FAERS Database and Literature Review.

JAK阻害薬で皮膚リンパ腫の安全性シグナルが示唆

対象DB：FAERS

10. Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

SGLT2阻害薬で切断・壊疽の安全性シグナル検出

対象DB：FAERS

11. Fatigue Associated with Trastuzumab Deruxtecan in Solid Tumors: A Meta-Analysis and Pharmacovigilance Signal Detection Study.

トラスツズマブデルクステカンで疲労が高頻度・早期に発現

対象DB：FAERS,JADER

12. Myocardial Infarction, Pulmonary Embolism, and Deep Vein Thrombosis Following Testosterone Cypionate Use: A Pharmacovigilance Study.

テストステロン投与で心血管リスク増加は明確でない

対象DB：FAERS

13. COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS.

COVIDワクチン後の自己免疫リウマチ疾患増加は認めず

対象DB：FAERS,VAERS

14. Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study.

CAR-T治療は致死的副作用が多様で予後影響が大きい

対象DB：FAERS,VigiBase

15. Comparative analysis of adverse events associated with epirubicin and doxorubicin: An observational study based on FDA Adverse Event Reporting System (FAERS) following STROBE guidelines.

乳癌化学療法でエピルビシンとドキソルビシンの副作用差を確認

対象DB：FAERS

16. Adverse events associated with cyclophosphamide: A pharmacovigilance study using the FDA adverse event reporting system.

CHOP療法で血液障害中心に新規副作用シグナルを検出

対象DB：FAERS

17. Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.

GLP-1作動薬の皮膚副作用は少ないが薬剤差あり

対象DB：FAERS

18. Hepatotoxicity associated with anti-neoplastic agents: a pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System database.

抗がん薬の肝障害は初期発症多く一部で重篤化

対象DB：FAERS

19. Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System database.

COVID抗ウイルス薬で投薬ミスが重篤転帰と関連、特にモルヌピラビルで多い

対象DB：FAERS

20. Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database.

デノスマブ顎骨壊死は高用量や併用薬でリスク増大

対象DB：FAERS

21. Post-marketing safety assessment of epinephrine: an analysis of the US FDA adverse event reporting system.

エピネフリンで即時発症の新規副作用シグナル多数検出

対象DB：FAERS

22. Vonoprazan-related adverse events: a pharmacovigilance study based on the FDA adverse event reporting system.

ボノプラザンで早期副作用多く新規安全性シグナルも示唆

対象DB：FAERS

23. From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases.

デュピルマブ治療で酒さ様皮疹の副作用シグナルが示唆

対象DB：FAERS

24. Cardiovascular Medications and Dementia Risk in Older Adults: A Literature Review and Disproportionality Analysis Using OpenVigil FAERS Data.

循環器薬の一部で認知症関連副作用シグナルを検出

対象DB：FAERS

25. Disproportionality analysis of dermatologic adverse events associated with nirogacestat: Insights from the U.S. Food and Drug Administration Adverse Event Reporting System.

ニロガセスタットで皮膚系副作用シグナルを検出

対象DB：FAERS

26. Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD.

ゾピクロン系睡眠薬で自殺関連事象の報告が多く男性で高リスク

対象DB：JADER

27. Risk factors for zolbetuximab-associated nausea and vomiting: a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database.

ゾルベツキシマブで悪心嘔吐多く、若年女性で高リスク

対象DB：JADER

28. Topically administered macrocyclic lactone products, including eprinomectin, demonstrate comparable neurological safety in cats based on pharmacovigilance data.

猫用外用寄生虫薬で神経系副作用頻度は薬剤間で同等

対象DB：EudraVigilance

29. Comparative Real-World Safety Profiles of Six Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis.

SSRIは薬剤ごとに副作用特性が異なり使い分け重要

対象DB：VigiBase

30. CXCR6(+) T Cells Drive Immune Checkpoint Inhibitor Myocarditis.

抗LAG-3/PD-1併用で心筋炎リスク増、CXCR6陽性T細胞が病態中核

対象DB：VigiBase

31. Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase).

幻覚薬は実地使用で精神系副作用報告が多く依存関連が目立つ

対象DB：VigiBase

32. Robotic versus video-assisted thoracoscopic lobectomy/segmentectomy: multilevel analysis in Japan.

肺癌手術でロボットとVATSの安全性は同等、換気わずかに増

対象DB：DPC

33. Recombinant Human Soluble Thrombomodulin and In-Hospital Mortality in Acute Pancreatitis With Disseminated Intravascular Coagulation: A Japanese Nationwide Study.

急性膵炎DIC合併例でrTM投与は院内死亡を低下

対象DB：DPC

34. Trends in mortality and major adverse cardiovascular events following incident acute myocardial infarction.

AMI後の死亡は低下する一方、心不全・脳卒中は増加

対象DB：CPRD

35. Diagnosis and management of migraine in adults: a population-based study in England.

英国一次診療で片頭痛は診断・予防治療が不十分

対象DB：CPRD

36. Assessment of a Modified High-Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX-2 Inhibitors.

入院データ併用HDPSでCOX-2阻害薬の消化管出血低リスク再現

対象DB：CPRD

37. Therapeutic Strategies After Discontinuation of Valproate By Females with Epilepsy of Child-Bearing Potential: An Insurance Claims Database Study in France and the United Kingdom.

妊娠可能女性のバルプロ酸中止は約半数で成功し、他剤単剤化が有効

対象DB：CPRD

38. Healthcare Resource Utilization and Corresponding Costs of Respiratory Syncytial Virus Hospital Episodes Before the Age of Two in England, 2015-2019.

RSV乳児感染は医療利用と費用負担が大きい

対象DB：CPRD

39. Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort study.

知的障害者はがん受診・治療が少なく予後不良

対象DB：CPRD

40. Emulating a Randomized Controlled Trial of Long-Acting Insulins and Cardiovascular Events Using Real-World Data for Patients With Type 2 Diabetes.

実臨床データでデグルデクとグラルギンの心血管リスクは同等

対象DB：CPRD

41. Current hypertension epidemiology and contemporary approaches using the "Real-World Evidence Cycle" framework.

高血圧は生活・社会・環境要因が関与し実地データ活用が重要

対象DB：DeSC